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Background: The prescription of antipsychotics (AP), and especially second generation AP, is increasing worldwide
in the pediatric population. Most prescriptions are off-label and despite the identification of frequent and potentially
severe adverse events (AE), there are only a few guidelines for the safety management. France is one of the countries
with no official safety guidelines.
Methods: Psychotropic drug-naive adolescents (13–18 years), hospitalized for an acute psychotic episode and treated
with a second-generation antipsychotic were consecutively included in a prospective cohort study. Patients were
assessed for their AE at baseline, 2, 6 and 12 weeks after the introduction of drug.
Results: The majority of patients was treated with risperidone (n = 13), 2 with aripiprazole. The principal findings are:
(1) A high incidence of neuromuscular AE: 8/15 muscle weakness, 8/15 extrapyramidal syndrome, 6/15 akathisia, 3/15
oro-facial acute dystonia; (2) Severe catatonia symptoms in 2 patients despite a low to moderate treatment dose,
requiring transfer in intensive care unit for one; (3) Weight gain and significant increase of the BMI for all 13 patients
who had a 12 weeks follow-up.
Conclusion: All adolescents experienced AE, with significant weight gain being observed in all patients who
completed the 12-week follow-up. The fact that our patient population was first episode drug naïve may partially
explain this observation. Despite the limitation due to the small sample size of this prospective short-term study,
such findings are important to report and warrant further research.
Clinical and research implication: Because of the lack of naturalistic follow up studies of antipsychotic treatments
in AP-naive children and adolescents and the absence of safety guidelines for the pediatric population in France, we
decided to continue our research at a national level. We therefore started a prospective, naturalistic and multicenter
study funded by the French National Agency for Medicines and Health Products Safety (ANSM). Study purpose is to
evaluate the incidence of adverse events related to antipsychotic drugs in AP-naive children and adolescents. In
addition, we aim to provide further evidence for the necessity of national safety guidelines for AP prescription in the
pediatric population.
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The prescription of psychotropics has increased in the
pediatric population all over the world since about
15 years. This increase is widely varying depending on
the country and molecules, ranging from 1.5- to 5-times
in many European countries and the United States [1,2].
In France the frequency of annual psychotropic prescrip-
tions in children and adolescents is about 2.2% [2]. The
increase in antipsychotic (AP) use is explained by a dra-
matic increase in atypical or second-generation AP
(SGA) use, while typical or first-generation AP (FGA)
prescriptions decreased [3]. SGA have a comparable effi-
ciency to FGA with better neuromuscular safety [4].
Many AP medications in the pediatric population are
prescribed off-label, especially in very young children
[5,6]. Prescriptions are therefore frequently unsupported
by rigorous scientific evidence. SGA drugs are actually
widely used to treat many psychiatric disorders such as
schizophrenia, bipolar, autistic spectrum, attention def-
icit hyperactivity or behavior disorders in the pediatric
population [7-9]. However, the pediatric literature data
show several adverse events (AE) in children and ad-
olescents treated with AP [10-14]: muscular (muscle
weakness, extrapyramidal syndrome, akathisia, dystonia,
dyskinesia, catatonia), metabolic (weight gain, obesity,
dyslipidemia, hyperglycemia, diabetes, insulin resistance,
hypertriglyceridemia, hypercholesterolemia) and endo-
crine AE (hyperprolactinemia, vitamin D deficiency).
Children treated with SGA are more likely than adults to
experience AE. Woods et al. [15] studied more than
4 million prescriptions of olanzapine. They observed
that the relative risk of sedation, weight gain, dystonia
and tardive dyskinesia is 2 to 5 times greater in children
or adolescents than in adults. Additionally, only few pro-
spective studies examine antipsychotic adverse events in
naive pediatric populations [16-18]. Several European
and American authors are worried about long-term ef-
fects of antipsychotic medication on children’s health and
recommend more safety guidelines and management of
adverse events [19-26]. In fact, there are currently few
guidelines for the management of adverse events in youth
treated by antipsychotics [27-29]. On the European level,
the lack of official guidelines for standardized follow-ups
in the pediatric population is surprising given the prob-
ably higher relative risk of AE in this population. Further-
more, the incidence of AE in a drug-naive population is
less well documented, as the typical study populations
consist of pediatric patients who have already been ex-
posed to an antipsychotic drug [30,31]. In France, since
2007 only two second-generation antipsychotics have
been granted market authorization: risperidone for severe
behavioral disorders from 5 years of age; and aripiprazole
for schizophrenia from the age of 15 years and recently
for maniac episodes associated with bipolar I disorderfrom the age of 13. The frequency of antipsychotic off-
label prescriptions is as high as 69% in French university
pediatric hospitals [32]. In March 2010, the French Na-
tional Agency for Medicines and Health Products Safety
(Agence nationale de sécurité du médicament et des pro-
duits de santé, ANSM) recommended cardiometabolic
monitoring for all adult subjects treated with psycho-
tropic drugs. There is no official recommendation for the
safety monitoring in the pediatric population. This is
paradoxical, since this population is at high risk of ad-
verse events. In addition, adverse events during AP use in
children are often poorly and insufficiently monitored in
France in general practice.
Clinical studies
Preliminary study
In our own clinical experience, based on a university in-
patient unit specifically aimed to treat young adolescents
with a first psychotic episode, we have observed that
adverse events (AE) such as weight gain, acute dystonia
and catatonia were very common in these patients
treated for the first time with SGA. We therefore
undertook a naturalistic prospective cohort study in
the University Children and Adolescent Psychiatric
Department of Nice, France, in order to evaluate the inci-
dence of AE related to SGA and we present the main re-
sults observed in our clinical population. This psychiatric
department is the only inpatient adolescent psychiatric
facility serving the one million and a half inhabitants of
the French department of the Alpes-Maritimes. Inpatient
psychotropic naive adolescents presenting a first acute
psychotic episode and treated with a SGA were consecu-
tively included in the study over a 12-month period from
July 2009 to July 2010. Each patient was followed for
12 weeks.
The study was approved by Lenval Children's Hospital
Scientific Committee. The following inclusion criteria were
used: (1) male or female inpatient; (2) aged between 13 and
18 years; (3) requiring a SGA treatment; and (4) never
before treated with any psychotropic medication. The
follow-up included 4 visits: at baseline (W0), in the
48 hours before the introduction of the SGA, at 2
(W2), at 6 (W6), and at 12 weeks (W12) after the
introduction of the SGA (Figure 1). The same investigator
who was experienced in the use of the standardized rating
scales assessed all adolescents. The clinical diagnosis was
confirmed by Kiddie-SADS (2002 version), and several
psychometric assessments were performed: Brief Psychiatry
Rating Scale (BPRS), Positive and Negative Syndrome Scale
(PANSS), Scale for the Assessment of Negative Symptoms
(SANS), Young Mania Rating Scale (YMRS), Montgomery
and Asberg Depression Rating Scale (MADRS) [33-37].
Neuromuscular AE were documented with the help of
the Extrapyramidal Symptom Rating Scale (ESRS) and the
Figure 1 Flow chart preliminary study. Flow chart of the preliminary study (Assessment of adverse events in a naive pediatric population
presenting psychosis and treated with a second-generation antipsychotic). A prospective study with a 12-weeks follow-up. BFCRS: Bush Francis
Catatonia Rating Scale; BPRS: Brief Psychiatric Rating Scale; ECG: Electrocardiogram; ESRS: Extrapyramidal Symptom Rating Scale; K-SADS: Schedule
for Affective Disorders and Schizophrenia for School Age Children; MADRS: Montgomery and Asberg Depression Rating Scale; PANSS: Positive and
Negative Syndrome Scale; SANS: Scale for the Assessment of Negative Symptoms; SGA: Second-Generation Antipsychotic; YMRS: Young Mania
Rating Scale.
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All laboratory assessments were performed by the
same university department laboratory (complete blood
count, liver enzymes, creatine phosphokinase, fasting
glycemia, cholesterol (HDL, LDL, total), triglycerides,
and prolactin) at baseline and at W12. Fifteen adoles-
cents, 8 males and 7 females, were included. Their
average age (±SD) was 14.9 ± 1.38 years. Thirteen were
treated with risperidone, and two with aripiprazole. The
average oral dose was 2.5 ± 1.6 mg/d for risperidone
and 7.5 ± 2.4 mg/d for aripiprazole throughout the
follow-up. At baseline, DSM-IV-R diagnoses were: acute
psychotic episode (15/15), schizophrenia (8/15), mood
disorder (3/15), severe anxiety disorder (2/15) and bor-
derline personality disorder (2/15).
We observed a high incidence of neuromuscular AE
during the follow-up, leading to the discontinuation of
AP treatment (risperidone) in 3 patients (catatonia 2/3,
acute oro-facial dystonia 1/3). Muscle weakness was
reported in 8/15 subjects, extrapyramidal syndrome
in 8/15, akathisia in 6/15 and acute oro-facial dystonia in
3/15.Severe catatonia symptoms were observed in 2 pa-
tients with paranoid schizophrenia at the 4th and 7th day
of treatment while receiving a low to moderate dose of
risperidone (1.5 and 2 mg respectively). Both patients
presented stupor, mutism, staring, catalepsy and rigidity.
In addition, verbigeration and withdrawal with refusal
to eat and drink was a clinical feature in the first pa-
tient, and echolalia and impulsivity in the second one.
Patients did not have fever or dysfunctions of the auto-
nomic nervous system. They presented high scores on
the Bush Francis Catatonia Rating Scale (17 and 12
respectively). SGA was immediately stopped and patients
received clonazepam at dose 0.05 mg/kg/d. The first pa-
tient had to be transferred to the intensive care unit for
hypoglycemia and dehydration in order to receive intra-
venous treatment.
One patient presented acute oro-facial dystonia. AP
treatment was stopped and the patient received anti-
cholinergic medication (one dose of intramuscular tro-
patepine 10 mg).
Moderate akathisia was present in 6 patients, some-
times starting as early as 2 weeks of SGA treatment.
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tom Rating Scale (ESRS).
For all patients - with the exception for one patient
who developed catatonia - creatine phosphokinase was
normal during follow up despite of a significant increase
(p = 0.03, Wilcoxon test). No correlation was detected
between this increase and neuromuscular AE (muscle
weakness, extrapyramidal syndrome, akathisia).
The 12 patients who completed the 12 weeks follow-
up presented a significant weight gain with 51.1 ±
8.5 kg at W0 and 59.0 ± 11.2 kg at W12 (p = 0.002,
Wilcoxon test). The BMI increased significantly from
19.0 ± 2.5 at W0 to 21.7 ± 3.5 at W12 (p = 0.002). The
observed weight gain of about 8 kg during 12 weeks
is higher than in two other pediatric studies of com-
parable duration (3,9 et 5,3 kg for risperidone [40,30];
4,4 kg for aripiprazole [30]; this might be explained
by the small subject number or dose differences in our
study.
No abnormalities were observed for the other moni-
tored parameters, including lipid values.
In summary, we observed in our study many and
serious adverse events despite the small sample size of
15 subjects. The particularity of this study is that all
patients presented a first psychotic episode and had
never been exposed to antipsychotic and/or other psy-
chotropic medications before, which might partially
explain this observation. For all these reasons and be-
cause of the lack of naturalistic follow-up studies of anti-
psychotic treatments in naive children and adolescents inFigure 2 Flow chart ETAPE study. ETAPE Study (Assessment of adverse e
prospective multicenter naturalistic study with a 12-months follow-up which
Scale; AP: Antipsychotic; BARS: Barnes Akathisia Rating Scale; BFCRS: Bush Fr
CGI-S: Clinical Global Impressions Scales; ECG: Electrocardiogram; HAQ: Help
Schizophrenia for School Age Children; MINI: Mini International Neuropsych
Questionnaire of Eating and Weight Patterns; SAS: Simpson and Angus ScaleFrance, we wanted to continue studying at the national
level.
A multicenter prospective naturalistic study in
antipsychotic naive children (ETAPE Study)
In order to continue our safety monitoring project we
have started a prospective, naturalistic and multicenter
study to evaluate the incidence of adverse events related
to the use of antipsychotic drugs in AP naive children and
adolescents in France (ETAPE, Etude de la Tolérance des
AntiPsychotiques chez l’Enfant) [41,42]. This study is
funded by the French National Agency for Medicines and
Health Products Safety (ANSM, Agence nationale de
sécurité du médicament et des produits de santé) and is
registered on ClinicalTrials.gov (NCT02007928) [43]. The
originality of this study lies in the inclusion of a AP naive
pediatric population aged 6 to 18 years in 11 French
pediatric psychiatry departments. Patients are included
since April 2013 and the inclusion period will be for about
2 years with a follow up of each subject of 12 months. 340
patients should be enrolled in the study. The inclusion cri-
teria are: (1) male or female, (2) aged from 6 to 18 years,
(3) treated by antipsychotic drug, (4) never having received
antipsychotic treatment before or having received AP for
less than 3 months which has been discontinued 6 months
prior to the study. Assessments are performed at the be-
ginning of antipsychotic treatment and at 3, 6, 9 and
12 months after the introduction of antipsychotic drug
(Figure 2). Diagnosis is made by the child psychiatrist
and confirmed by the Kiddie - SADS scale (Schedule forvents in a naive pediatric population treated with an antipsychotic). A
started in France in April 2013. AIMS: Abnormal Involuntary Movement
ancis Catatonia Rating Scale; CGAS: Clinical Global Assessment Scale;
ing Alliance Questionnaire; K-SADS: Schedule for Affective Disorders and
iatric Interview; PAERS: Pediatric Adverse Event Rating Scale; QEWP:
; SDS: Sheehan Disability Scale.
Menard et al. Child and Adolescent Psychiatry and Mental Health 2014, 8:18 Page 5 of 7
http://www.capmh.com/content/8/1/18Affective Disorders and Schizophrenia for School Age
Children), M.I.N.I. (The Mini International Neuro-
psychiatric Interview) or M.I.N.I.-Kid (depending on the
age of patient) based on DSM-IV-R criteria. An exhaustive
investigation of AE is made using the Pediatric Adverse
Event Rating Scale which has been designed for the sys-
tematic identification of AE in the pediatric population
treated with psychotropics in clinical studies by the Child
and Adolescent Psychiatry Trials Network [44] and trans-
lated in French by two different experts. Neuromuscular
safety is assessed by the following clinical scales: Abnor-
mal Involuntary Movement Scale (AIMS) [45] for dys-
kinesia, Barnes Akathisia Rating Scale (BARS) [46] for
akathisia, Simpson and Angus Scale (SAS) [47] for extra-
pyramidal side effects, Bush Francis Catatonia Rating Scale
(BFCRS) for catatonia. Several somatic parameters are
monitored (weight, height, BMI, waist circumference,
blood pressure, temperature, Tanner pubertal stage). On
each visit, blood samples are analyzed for complete blood
count, liver enzymes, creatine phosphokinase, fasting gly-
cemia, cholesterol (HDL, LDL, total) and triglycerides. The
study also includes a follow-up of thyroid function, prolac-
tin, insulin, HOMA, HbA1C, vitamin D and C-reactive
protein. Four self-administered questionnaires are proposed
to child and parent: (1) Sheehan Disability Scale (SDS) for
the evaluation of functional impairment in school, social
and family life [48], (2) Helping Alliance Questionnaire
(HAQ) to assess the relation between the patient, his family
and the therapist [49], (3) Pediatric Adverse Event Rating
Scale (PAERS) for the evaluation of side effects, (4) Ques-
tionnaire of Eating and Weight Patterns (QEWP) to specify
eating disorders like bulimia or binge eating [50]. An elec-
trocardiogram with the measurement of the QT interval is
performed at baseline, 6 and 12 months.
Conclusion
In the pediatric population, the use of antipsychotic
drugs has been continously increasing over the last de-
cade. In France, prescriptions are frequently off-label
and starting more and more in young children. Adverse
events are often not optimally monitored and without
systematic follow-up. In addition, the lack of studies in
children also leads to a safety concern.
The data of our preliminary study underline a high
prevalence of neuromuscular AE in fifteen psychotropic
drug naive inpatient adolescents treated with SGA for a
first psychotic episode. We therefore started a multicen-
ter prospective and naturalistic study to evaluate AP ad-
verse events in naive children and adolescents in France.
The results of ETAPE’s study will have a major impact
in terms of public mental health services in our country
and must help to develop official recommendations for
antipsychotic treatment and its safety monitoring in the
pediatric population.Implications and contribution
Beyond the available literature, more research is urgently
needed about adverse events of antipsychotics in the
pediatric population in order to develop official recom-
mendations. However, enough is known to emphasize
the necessity of thorough and systematic monitoring of
AE in this vulnerable population. Furthermore, in the
light of the growing trend to prescribe these drugs to
children and adolescents, practitioners need to be aware
of the necessity of optimal safety management.
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